AMS Planning, Inc.は北大発認定スタートアップ企業です

AMS Announces 100 Million JPY in Series A Fundraising

November 9, 2022
AAMS undertakes private capital fundraising in support of nuclear medicine development

TOKYO, Japan – November 9, 2022 – Advanced Medical Science-Planning (AMS), a Japanese nuclear medicine start-up company, announced today the closing of a Series A financing round totaling ¥100 million (USD $1 Million). MIRAISOUZOU (MIRAI), a Tokyo-based Venture Capital Firm, led the fundraising round. The financing will accelerate AMS’ PMDA process for bringing 68Ga-PSMA-PET diagnosis for prostate cancer to Japan, including preclinical and clinical trials. The investment also enables AMS to explore new radiopharma assets.

“We are grateful for the support of MIRAI in helping us bring innovative radiopharmaceuticals to Japan, such as 68Ga-PSMA-PET for prostate cancer, and develop new drugs from Japan,” said Yuichiro Sugawara, AMS’s Founder and CEO. “We are also thrilled to collaborate with MIRAI’s networks related to the Tokyo Institute of Technology as well as Tokyo Medical and Dental University in the future, as the recent announcement of a basic agreement for integration between two prestigious universities.

Hiroyuki Okada, CEO of MIRAI Co-Founder and CEO noted that “MIRAI is excited to expand our healthcare investments with AMS and Hokkaido University Nuclear Medicine Venture, targeting the intersection of the nuclear and medicine industry. We also are excited about the game-changing product to bring new cancer diagnosis and treatment options to the market. We are delighted to be on board at this pivotal point for AMS.”

About AMS

Advanced Medical Science-Planning, Inc (AMS) is a Japanese nuclear medicine start-up company seeking to transform Japan’s nuclear industry and provide new business and economic growth opportunities following the March 2011 Fukushima Nuclear Power Station Accident. Pursuant to the corporate mantra “Cure Better, Innovation,” AMS will deploy nuclear medicine-based Theranostics, which combines both therapeutic and diagnostic capabilities in one dose for cancer treatment, as well as pairing Theranostics with artificial intelligence to enhance their effectiveness in terms of precision oncology. As the first step in our growth strategy, AMS is engaged in a phased approach to bring 68Ga-PSMA-PET diagnosis for prostate cancer to Japan— a diagnosis tool that is currently available in the United States, Europe, and Australia.

Visit the website, at Contact:


MIRAISOUZOU (MIRAI) was established as a private university-related VC in 2014 and signed an organizational cooperation agreement with the Tokyo Institute of Technology (Tokyo Tech) in 2016. MIRAI has managed two funds and three start-ups that MIRAI has invested in went public and one of which achieved M&A. MIRAI has a unique ecosystem such as a start-up studio business and education business in collaboration with Kosen Career in addition to VC business, delivering synergy among the three.

For more information, visit